



May 12, 2021

To whom it may concern:

Company Name:  **TAIYO HOLDINGS CO., LTD.**  
Representative: Eiji Sato, President and CEO  
(Code: 4626, Listed on First Section of  
Tokyo Stock Exchange)  
Inquiries: Sayaka Tomioka, Executive Officer,  
General Manager of Corporate Planning  
Department  
Tel: +81-3-5953-5200 (main line)

## **Notice of Partial Correction to “Consolidated Financial Result Digest FY2021 Q4 (Fiscal Year Ending March 31, 2021)”**

TAIYO HOLDINGS CO., LTD. (hereinafter, “Taiyo Holdings”) hereby announces that there were some matters to be corrected in the disclosed material on April 30, 2021, so we will correct it as follows.

### 1. Reason for correction

In the material “Consolidated Financial Result Digest FY2021 Q4 (Fiscal Year Ending March 31, 2021)” disclosed on April 30, 2021, there was some errors in the information in “Performance by Segment” (page 5) and “Consolidated Earnings Forecast for the Fiscal Year Ending March 2022” (page 28), hence the correction.

### 2. Details of the correction

#### “Performance by Segment” (page 5)


From the first quarter of the fiscal year ending March 2021, some expenses that were previously included in company-wide expenses are allocated to each report segment. The EBITDA and EBITDA margins have been corrected because the figures for the previous fiscal year were not allocated in this manner.

#### “Consolidated Earnings Forecast for the Fiscal Year Ending March 2022” (page 28)


There was an error in the EBITDA figure for the fiscal year ending March 2021 for the Medical and Pharmaceuticals business, so we have corrected it.

Please refer to the attached sheet for details. The corrected parts are underlined in red.

“Performance by Segment” (page 5)  
 【Before correction】



【After correction】



"Consolidated Earnings Forecast for the Fiscal Year Ending March 2022" (page 28)  
 【Before correction】

## Consolidated Earnings Forecast for the Fiscal Year Ending March 2022

### Earnings forecast by segment

Unit : JPY Million

	FY2021 Electronics Materials Full year Result	FY2022 Electronics Materials Full year Forecast	Change	%	FY2021 Medical and pharmaceuticals Full year Result	FY2022 Medical and Pharmaceuticals Full year Forecast	Change	%
<b>Net Sales</b>	53,096	58,400	5,304	10%	24,553	23,900	-653	-3%
<b>Operating Income</b>	11,208	12,300	1,092	10%	3,837	1,400	-2,437	-64%
Exchange rate of JPY/USD	106.2	108	1.8		106.2	108	1.8	
<b>EBITDA</b>	12,970	14,300	1,330	10%	8,669	6,000	-2,669	-31%
<b>Operating Income Margin</b>	21%	21%			16%	6%		
<b>EBITDA Margin</b>	24%	24%			35%	25%		

Copyright © TAIYO HOLDINGS CO., LTD. All Rights Reserved.

 TAIYO HOLDINGS CO., LTD. 28

【After correction】

## Consolidated Earnings Forecast by Segment for the Fiscal Year Ending March 2022

### Earnings forecast by segment

Unit : JPY Million

	FY2021 Electronics Materials Full year Result	FY2022 Electronics Materials Full year Forecast	Change	%	FY2021 Medical and pharmaceuticals Full year Result	FY2022 Medical and Pharmaceuticals Full year Forecast	Change	%
<b>Net Sales</b>	53,096	58,400	5,304	10%	24,553	23,900	-653	-3%
<b>Operating Income</b>	11,208	12,300	1,092	10%	3,837	1,400	-2,437	-64%
Exchange rate of JPY/USD	106.2	108	1.8		106.2	108	1.8	
<b>EBITDA</b>	12,970	14,300	1,330	10%	8,668	6,000	-2,668	-31%
<b>Operating Income Margin</b>	21%	21%			16%	6%		
<b>EBITDA Margin</b>	24%	24%			35%	25%		

Copyright © TAIYO HOLDINGS CO., LTD. All Rights Reserved.

 TAIYO HOLDINGS CO., LTD. 28